This trial is evaluating whether Treatment will improve 1 primary outcome and 3 secondary outcomes in patients with Hepatobiliary Disorders. Measurement will happen over the course of Within 6 months after study drug administration during data analysis phase of study.
This trial requires 26 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
"These disorders may be classified by location of onset and by histological type. In the most common forms, portal hypertension and cholestasis of any cause are involved. Biliary obstruction may present with jaundice and pruritus (itch). A minority of these disorders are caused by intrahepatic or extrahepatic malignancy. Rarely cirrhosis, and very rarely steatosis and fibrosis, cause symptoms. The hepatic manifestations may be symptomatic even in the absence of underlying liver disease." - Anonymous Online Contributor
"The incidence of these conditions warrants careful screening in the general population. Abnormal liver function tests indicate the presence of hepatocellular inflammation. With early treatment, the majority of patients will have a significant decrease in their liver function." - Anonymous Online Contributor
"Overwhelming data support that HBV and HCV are two of the most relevant risk factors for development of hepatobiliary disorders. In addition to virus-related risk factors, other risk factors were identified, of which most deserve deeper investigation." - Anonymous Online Contributor
"Signs of portal hypertension include hepatic enlargement (particularly in cirrhosis or in patients with obstructive jaundice), enlargement of the spleen, ascites, splenomegaly and portal tenderness. In acute situations such as portal vein thrombosis, hepatomegaly and splenomegaly occur without tenderness while ascites is present. Abdominal fullness (painful abdominal fullness) is a sign of ascites secondary to portal hypertension and, with this, the diagnosis of ascites." - Anonymous Online Contributor
"Lifestyle changes should be first line for many, if not all, patients with liver diseases and cholelithiasis. Medications can be used to treat pruritus, pain and symptoms of cholelithiasis. In the more serious conditions (cirrhosis, fibrosis or portal hypertension) drugs will be reserved for specific patients or complications. Surgery will be indicated only in specific cases." - Anonymous Online Contributor
"Chronic liver diseases cause more than 1 of every 100 deaths in the United States and this number is expected to rise with time. Hepatobiliary surgeons and other clinicians are called upon to educate the public and the healthcare system about the devastating burden these diseases cause." - Anonymous Online Contributor
"There is moderate evidence for the safety of long-term iron and ferritin treatment for non-anemic ID in this population. There is weak evidence that long-term iron or ferritin therapy for ID may have an important adverse effect on short-term ID." - Anonymous Online Contributor
"There are many different medical conditions for which clinical trials are available. Doctors should consider the risk-benefit ratio as they decide whether a patient fits the criteria to participate in a clinical trial. It is important for patients to be informed so their physicians know when to recommend testing." - Anonymous Online Contributor
"Most of the disorders do run in families, but not all of them. The inheritance patterns can be extremely variable. Most of the disorders are caused by environmental factors that accumulate to make the predisposition to development and to disease expression. Inherited disorders can be a clue into the underlying disease mechanism. It is worthwhile to continue to investigate the molecular basis of these diseases in order to develop a clear preventive concept on the first place. These diseases could be better understood in the light of genetic studies to identify the loci that could be mapped in families, especially in a high-resolution manner. Then, by use of molecular techniques, the genetic factors that predispose to these diseases could be identified to give a clue on the disease mechanism." - Anonymous Online Contributor
"Although the use of the treatments and combination of treatments is not common in the treatment of cholestatic jaundice, most of the observed studies have shown that in terms of efficacy to treat cholestatic jaundice no significant difference can be noted between any treatment with any other treatment. Therefore, to recommend these treatments, a thorough analysis needs to be carried out. The type of treatment chosen would depend on the severity of the disease." - Anonymous Online Contributor
"Patients with serious hepatobiliary disorders frequently experience symptoms, which can be challenging when diagnosing. A combination of clinical judgement, a good understanding of the disease course and high medical diagnostic and consultation skills are necessary for achieving the optimum management of severe hepatobiliary disorders." - Anonymous Online Contributor
"Treatment for choledocholithiasis may be accomplished by a percutaneous technique wherein the goal is to disrupt the stone by using ultrasound-guided laparoscopic or endoscopic retrograde cholangiopancreatography. In patients with hepatolithiasis, we recommend ERCP and biliary drainage under anesthesia for biliary clearance followed by an ultrasound study of the biliary ducts during the following 24 to 48 hours with a repeat ERCP if necessary. As in the case of the pancreas, the primary goal is to disrupt the stone by using cholangioscopy and electrohydraulic lithotripsy." - Anonymous Online Contributor